咪唑-2-羧酸甲酯 | 17334-09-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 咪唑-2-羧酸甲酯
• 中文别名: 1H-咪唑-2-羧酸甲酯；咪唑-2 -羧酸甲酯
• 英文名称: methyl 1H-imidazole-2-carboxylate
• 英文别名: Imidazol-2-carbonsaeure-methylester；2-(Methoxycarbonyl)-imidazol
• CAS: 17334-09-7
• 化学式: C₅H₆N₂O₂
• mdl: MFCD06203842
• 分子量: 126.115
• InChiKey: JTAQRDQNFANUEK-UHFFFAOYSA-N

物化性质

• 熔点：
  195.5-196.0 °C
• 沸点：
  262.6±23.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 1h-imidazole-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 1h-imidazole-2-carboxylate
CAS number: 17334-09-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6N2O2
Molecular weight: 126.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  咪唑-2-羧酸甲酯 反应 3.0h， 以20%的产率得到5H,10H-二咪唑并[1,2-a:1,2-d]吡嗪-5,10-二酮
  参考文献：
  名称：

  Diazafulvenones. Thermal isomerizations and eliminations in alkoxycarbonyl and anilinocarbonyl derivatives of imidazole

  摘要：

  DOI：

  10.1021/jo00353a006
• 作为产物：
  描述：

  重氮甲烷 、 咪唑-2-甲酸 生成 咪唑-2-羧酸甲酯
  参考文献：
  名称：

  The structure of [C3H4N2]+· and [C5H5N2]+ ions formed from vinylimidazoles, studied by collisionally activated dissociation mass spectrometry

  摘要：

  AbstractMass spectra of the three isomeric vinylimidazoles have been compared and the structures of the fragment ions [C3H4N2]+· and [C5H5N2]+ have been investigated by collisionally activated dissociation mass spectrometry. The greater part of the non‐decomposing ions m/z 68 from 2‐vinylimidazole and from 2‐imidazolecarboxylic acid methyl ester, and a minor part of this ion formed from the free acid, all have the same structure: the imidazole ring system, with hydrogens at both nitrogen atoms but none at C(2). An analogous structure, with an ethyl group at C(2), is proposed for the m/z 93 ion from 2‐vinylimidazole.

  DOI：

  10.1002/oms.1210190105

文献信息

• Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists
  作者：Xuqing Zhang、Chaozhong Cai、Michael Winters、Michele Wells、Mark Wall、James Lanter、Zhihua Sui、Jingyuan Ma、Aaron Novack、Imad Nashashibi、Yuanping Wang、Wen Yan、Arthur Suckow、Hong Hua、Austin Bell、Peter Haug、Wilma Clapper、Celia Jenkinson、Joseph Gunnet、James Leonard、William V. Murray

  DOI：10.1016/j.bmcl.2017.06.028

  日期：2017.8

  A novel series of 5-membered heterocycle-containing phenylpropanoic acid derivatives was discovered as potent GPR120 agonists with low clearance, high oral bioavailability and in vivo antidiabetic activity in rodents.

  发现了一系列新型的五元含杂环苯丙酸衍生物，作为强效的GPR120激动剂，在啮齿类动物中具有低清除率，高口服生物利用度和体内抗糖尿病活性。
• Synthesis and antimuscarinic properties of some N-substituted 5-(aminomethyl)-3,3-diphenyl-2(3H)-furanones
  作者：Carl Kaiser、Ciro J. Spagnuolo、Theodore C. Adams、Vicki H. Audia、Andrea C. Dupont、Holia Hatoum、Valerie C. Lowe、Judith C. Prosser、Bonnie L. Sturm、Lalita Noronha-Blob

  DOI：10.1021/jm00101a019

  日期：1992.11

  selective antimuscarinic drugs with potential utility in the treatment of urinary incontinence associated with bladder muscle instability, a series of N-substituted 5-(aminomethyl)-3,3-diphenyl-2(3H)-furanones, conformationally-constrained lactone relatives of benactyzine, was prepared. The compounds were examined in several paradigms that measure muscarinic (M1, M2, and M3) receptor antagonist activity

  在一项旨在开发新的选择性抗毒蕈碱药物的研究中，该药物在治疗与膀胱肌不稳相关的尿失禁中具有潜在的实用性，一系列N-取代的5-（氨基甲基）-3,3-二苯基-2（3H）-呋喃酮，制备了受构造约束的贝内替嗪的内酯亲戚。在衡量毒蕈碱（M1，M2和M3）受体拮抗剂活性的几种范例中检查了这些化合物。研究了在这些测试中显示出效力和/或选择性的系列成员中的一些成员对豚鼠膀胱收缩，瞳孔散大和唾液分泌的影响。这些研究表明，将氨基官能团并入咪唑或吡唑环中会产生一些新颖，有效和选择性的抗毒蕈碱剂。咪唑位置2的适当烷基取代显着影响毒蕈碱，特别是M3受体活性，并可能反映相互作用的互补位点。一些化合物在膀胱造影（CMG）模型中选择性降低了膀胱压力，而没有产生散瞳和唾液效应。在这些体内方案中，该系列几种化合物的单独作用和不同作用表明，毒蕈碱受体亚型可能与先前表征的分子克隆亚群相对应。在本文中，讨论了一系列取代内酯的构效关系
• [EN] KRAS G12D INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12D
  申请人：MIRATI THERAPEUTICS INC

  公开号：WO2021041671A1

  公开（公告）日：2021-03-04

  The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12D的化合物。具体地，本发明涉及抑制KRas G12D活性的化合物，包括这些化合物的药物组合物以及使用方法。
• [EN] DNA POLYMERASE THETA INHIBITORS<br/>[FR] INHIBITEURS DE L'ADN POLYMÉRASE THÊTA
  申请人：ARTIOS PHARMA LTD

  公开号：WO2021123785A1

  公开（公告）日：2021-06-24

  The invention relates to heterocyclic derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.

  这项发明涉及杂环衍生物及其在癌症治疗和预防中的应用，以及含有这些衍生物的组合物和它们的制备方法。
• [EN] TRICYCLIC COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS TRICYCLIQUES ET LEUR UTILISATION
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2020244637A1

  公开（公告）日：2020-12-10

  Tricyclic compounds and their use are provided. More specifically, tricyclic compounds, pharmaceutical compositions containing them, methods for preparing them, and their use in therapy are also provided.

  提供了三环化合物及其用途。更具体地，还提供了三环化合物、含有它们的药物组合物、制备它们的方法，以及它们在治疗中的用途。